A Pilot Study Evaluating Steroid-Induced Diabetes after Antiemetic Dexamethasone Therapy in Chemotherapy-Treated Cancer Patients
0
조회
0
다운로드
2
인용
0
참고문헌
키워드
초록
Purpose Dexamethasone is a mainstay antiemetic regimen for the prevention of chemotherapyinduced nausea and vomiting. The aim of this pilot study was to assess the incidence of and factors associated with steroid-induced diabetes in cancer patients receiving chemotherapy with dexamethasone as an antiemetic. Materials and Methods Non-diabetic patients with newly diagnosed gastrointestinal cancer who received at least three cycles of highly or moderately emetogenic chemotherapy with dexamethasone as an antiemetic were enrolled. Fasting plasma glucose levels, 2-hour postprandial glucose levels, and hemoglobin A1C tests for the diagnosis of diabetes were performed before chemotherapy and at 3 and 6 months after the start of chemotherapy. The homeostasis model assessment of insulin resistance (HOMA-IR) was used as an index for measurement of insulin resistance, defined as a HOMA-IR 2.5. Results Between January 2012 and November 2013, 101 patients with no history of diabetes underwent laboratory tests for assessment of eligibility; 77 of these patients were included in the analysis. Forty-five patients (58.4%) were insulin resistant and 17 (22.1%) developed steroid-induced diabetes at 3 or 6 months after the first chemotherapy, which included dexamethasone as an antiemetic. Multivariate analysis showed significant association of the incidence of steroid-induced diabetes with the cumulative dose of dexamethasone (p=0.049). Conclusion We suggest that development of steroid-induced diabetes after antiemetic dexamethasone therapy occurs in approximately 20% of non-diabetic cancer patients; this is particularly significant for patients receiving high doses of dexamethasone.
Abstract
Purpose Dexamethasone is a mainstay antiemetic regimen for the prevention of chemotherapyinduced nausea and vomiting. The aim of this pilot study was to assess the incidence of and factors associated with steroid-induced diabetes in cancer patients receiving chemotherapy with dexamethasone as an antiemetic. Materials and Methods Non-diabetic patients with newly diagnosed gastrointestinal cancer who received at least three cycles of highly or moderately emetogenic chemotherapy with dexamethasone as an antiemetic were enrolled. Fasting plasma glucose levels, 2-hour postprandial glucose levels, and hemoglobin A1C tests for the diagnosis of diabetes were performed before chemotherapy and at 3 and 6 months after the start of chemotherapy. The homeostasis model assessment of insulin resistance (HOMA-IR) was used as an index for measurement of insulin resistance, defined as a HOMA-IR 2.5. Results Between January 2012 and November 2013, 101 patients with no history of diabetes underwent laboratory tests for assessment of eligibility; 77 of these patients were included in the analysis. Forty-five patients (58.4%) were insulin resistant and 17 (22.1%) developed steroid-induced diabetes at 3 or 6 months after the first chemotherapy, which included dexamethasone as an antiemetic. Multivariate analysis showed significant association of the incidence of steroid-induced diabetes with the cumulative dose of dexamethasone (p=0.049). Conclusion We suggest that development of steroid-induced diabetes after antiemetic dexamethasone therapy occurs in approximately 20% of non-diabetic cancer patients; this is particularly significant for patients receiving high doses of dexamethasone.
참고문헌 (25)
- Vigneri P, "Diabetes and cancer", Endocr Relat Cancer, 16, pp.1103~1123 (2009)
- Oyer DS, "How to manage steroid diabetes in the patient with cancer", J Support Oncol, 4, pp.479~483 (2006)
- Poulson J, "The management of diabetes in patients with advanced cancer", J Pain Symptom Manage, 13, pp.339~346 (1997)
- Hesketh PJ, "Chemotherapy-induced nausea and vomiting", N Engl J Med, 358, pp.2482~2494 (2008)
- "NCCN Clinical Practice Guidelines in Oncology: antiemesis. Version 2" (2014)[URL]
- Vardy J, "Side effects associated with the use of dexamethasone for prophylaxis of delayed emesis after moderately emetogenic chemotherapy", Br J Cancer, 94, pp.1011~1015 (2006)
- Fardet L, "Corticosteroidinduced adverse events in adults : frequency, screening and prevention", Drug Saf, 30, pp.861~881 (2007)
- Han HS, "A prospective multicenter study evaluating secondary adrenal suppression after antiemetic dexamethasone therapy in ccancer patients receiving chemotherapy: a Korean South West Oncology Group Study", Oncologist, 20, pp.1432~1439 (2015)
- Rafacho A, "Glucocorticoid treatment and endocrine pancreas function: implications for glucose homeostasis, insulin resistance and diabetes", J Endocrinol, 223, pp.49~62 (2014)
- Longo DL, "Harrison’s principles of internal medicine" (2011), McGraw-Hill Companies, Inc
- Matthews DR, "Homeostasis model assessment : insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man", Diabetologia, 28, pp.412~419 (1985)
- Kim CH, "Relative contributions of insulin resistance and beta-cell dysfunction to the development of Type 2 diabetes in Koreans", Diabet Med, 30, pp.1075~1079 (2013)
- 손장원, "Changing Clinical Characteristics according to Insulin Resistance and Insulin Secretion in Newly Diagnosed Type 2 Diabetic Patients in Korea", Diabetes and Metabolism Journal, 39(5), pp.387~394 (2015), 대한당뇨병학회[DOI]
- Yoo KE, "Awareness of the adverse effects associated with prophylactic corticosteroid use during docetaxel therapy", Support Care Cancer, 23, pp.1969~1977 (2015)
- Brunello A, "Hyperglycemia during chemotherapy for hematologic and solid tumors is correlated with increased toxicity", Am J Clin Oncol, 34, pp.292~296 (2011)
- Polonsky KS, "C-peptide as a measure of the secretion and hepatic extraction of insulin. Pitfalls and limitations", Diabetes, 33, pp.486~494 (1984)
- Weiser MA, "Relation between the duration of remission and hyperglycemia during induction chemotherapy for acute lymphocytic leukemia with a hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone", methotrexate-cytarabine regimen, 2004, pp.100, 1179~1185
- Meyerhardt JA, "Impact of diabetes mellitus on outcomes in patients with colon cancer", J Clin Oncol, 21, pp.433~440 (2003)
- van de Poll-Franse LV, "Less aggressive treatment and worse overall survival in cancer patients with diabetes : a large population based analysis", Int J Cancer, 120, pp.1986~1992 (2007)
- Barone BB, "Long-term all-cause mortality in cancer patients with preexisting diabetes mellitus : a systematic review and metaanalysis", JAMA, 300, pp.2754~2764 (2008)
- Yancik R, "Effect of age and comorbidity in postmenopausal breast cancer patients aged 55 years and older", JAMA, 285, pp.885~892 (2001)
- Luo J, "Fasting blood glucose level and prognosis in non-small cell lung cancer(NSCLC)patients", Lung Cancer, 76, pp.242~247 (2012)
- Nakazawa K, "Survival difference in NSCLC and SCLC patients with diabetes mellitus according to the first-line therapy", Med Oncol, 30, pp.367~ (2013)
- Tran TT, "Hyperinsulinemia, but not other factors associated with insulin resistance, acutely enhances colorectal epithelial proliferation in vivo", Endocrinology, 147, pp.1830~1837 (2006)
- Muller LM, "Increased risk of common infections in patients with type 1 and type 2 diabetes mellitus", Clin Infect Dis, 41, pp.281~288 (2005)